Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
Sales | 11,096,640 | 10,527,000 | 9,733,822 | 10,522,300 | 11,158,150 |
Cost of Goods | 2,925,330 | 2,619,550 | 2,569,700 | 3,713,700 | 2,769,620 |
Gross Profit | 8,168,600 | 7,826,150 | 7,164,110 | 7,402,578 | 8,388,530 |
Operating Expenses | 4,769,170 | 4,428,390 | 4,780,610 | 6,208,810 | 4,735,520 |
Operating Income | 3,402,470 | 3,479,610 | 2,384,212 | 600,490 | 3,653,630 |
Other Income | -262,090 | -287,230 | 11,488 | 476,730 | -96,760 |
Pre-tax Income | 3,140,380 | 3,192,380 | 2,395,700 | 1,077,220 | 3,556,870 |
Income Tax | 889,740 | 930,460 | 714,680 | 335,420 | 1,060,420 |
Net Income Continuous | 2,251,182 | 2,262,000 | 1,681,022 | 1,495,300 | 2,496,452 |
Net Income | $2,251,182 | $2,262,000 | $1,681,022 | $1,495,300 | $2,496,452 |
EPS Basic Total Ops | 1.08 | 1.16 | 0.80 | 0.74 | 1.18 |
EPS Basic Continuous Ops | 1.08 | 1.10 | 0.80 | 0.73 | 1.18 |
EPS Diluted Total Ops | 1.08 | 1.16 | 0.80 | 0.74 | 1.18 |
EPS Diluted Continuous Ops | 1.08 | 1.10 | 0.80 | 0.73 | 1.18 |
EBITDA(a) | $4,263,720 | $3,799,960 | $3,251,322 | $1,579,030 | $4,358,101 |